Status:
RECRUITING
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
Lead Sponsor:
Fudan University
Conditions:
Hematological Toxicity
Targeted Therapy
Eligibility:
All Genders
Brief Summary
This multicenter, real-world, observational study will retrospectively and prospectively collect real-world data related to the investigational drugs. We plan to observe 1000 patients and collect data...
Eligibility Criteria
Inclusion
- · The patients signed the informed consent and voluntarily participated in the study.
- A definite diagnosis of any type of breast cancer.
- Receiving or has completed targeted therapies.
- Investigator judged that the patient need to receive or had received treatment or prevention for CTIT, CIN or CRA induced by targeted therapies.
Exclusion
- · Pregnant or lactating women.
- Failure to understand the study or to obtain informed consent.
- The investigator determined other situations that are not suitable for inclusion.
Key Trial Info
Start Date :
July 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 10 2027
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06503380
Start Date
July 15 2024
End Date
June 10 2027
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhi-Ming Shao
Shanghai, Not US/Canada, China, 200032